AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31869755 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG group with levonorgestrel
Number of subjects: 20
Study 31869755 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG group with gestoden
Number of subjects: 20
Study 31869755 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG group during inactive pill with levonorgestrel
Number of subjects: 20
Study 31869755 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG group during inactive pill with drospirenon
Number of subjects: 20
Study 31869755 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG group during inactive pill with gestoden
Number of subjects: 20
Study 31869755 — intervention group
Group type: COMPARATOR
Intervention: Control group on COC
Number of subjects: 20
Study 31708182 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine (4 doses)
Number of subjects: 153
Study 31708182 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine (3 doses) plus 1 comparator vaccine dose
Number of subjects: 153
Study 31708182 — intervention group
Group type: COMPARATOR
Intervention: Comparator vaccine doses (4 doses)
Number of subjects: 153
Study 31708182 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine
Number of subjects: 153
Study 31708182 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS01-vaccinated immunogenicity controls with unknown or negative HIV status
Number of subjects: 153
Study 29367471 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg once daily)
Number of subjects: 156
Study 29367471 — intervention group
Group type: COMPARATOR
Intervention: voglibose (0.2 mg/meal thrice daily)
Number of subjects: 156
Study 26468636 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D prints
Number of subjects: 52
Study 26468636 — intervention group
Group type: COMPARATOR
Intervention: Cadaveric materials
Number of subjects: 52
Study 26468636 — intervention group
Group type: COMPARATOR
Intervention: Combined materials
Number of subjects: 52
Study 24443059 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of C-reactive protein (CRP)
Number of subjects: 296
Study 24443059 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of interleukin-6 (IL-6)
Number of subjects: 296
Study 24443059 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of C-peptide
Number of subjects: 296
Study 24443059 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of non-HMW adiponectin
Number of subjects: 296
Study 24443059 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of GLDH
Number of subjects: 296
Study 22616316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg of morphine (group M1)
Number of subjects: 112
Study 22616316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of morphine (group M2)
Number of subjects: 112
Study 22616316 — intervention group
Group type: COMPARATOR
Intervention: 0.9 percent sodium chloride (saline, group S)
Number of subjects: 112
Study 22616316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 percent levobupivacaine
Number of subjects: 112
Study 20045479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (single 6 mg dose)
Number of subjects: 78
Study 20045479 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/day)
Number of subjects: 78
Study 18022544 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (unconjugated and conjugated)
Number of subjects: 0
Study 18022544 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody conjugates
Number of subjects: 0
Study 16222009 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 258
Study 16222009 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 258
Study 11856086 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg intravenously)
Number of subjects: 14
Study 11856086 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 11856086 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 14
Study 10438182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimactane (600 mg)
Number of subjects: 19
Study 10438182 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic rifampicin preparations (600 mg)
Number of subjects: 19
Study 10438182 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro dissolution profiles
Number of subjects: 19
Study 10438182 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight of volunteers
Number of subjects: 19
Study 7563559 — intervention group
Group type: EXPERIMENTAL
Intervention: 11‐mg/d dose of transdermal nicotine
Number of subjects: 71
Study 7563559 — intervention group
Group type: EXPERIMENTAL
Intervention: 22‐mg/d dose of transdermal nicotine
Number of subjects: 71
Study 7563559 — intervention group
Group type: EXPERIMENTAL
Intervention: 44‐mg/d dose of transdermal nicotine
Number of subjects: 71
Study 7563559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 7563559 — intervention group
Group type: EXPERIMENTAL
Intervention: 44‐mg/d dose of nicotine patch therapy
Number of subjects: 71
Study 7563559 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percentage of cotinine replacement
Number of subjects: 71
Study 7563559 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 2 patch dose
Number of subjects: 71
Study 2346334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate
Number of subjects: 136
Study 2346334 — intervention group
Group type: COMPARATOR
Intervention: Oral methotrexate
Number of subjects: 136
Study 2346334 — intervention group
Group type: COMPARATOR
Intervention: 24 Gy cranial irradiation
Number of subjects: 136
Study 2346334 — intervention group
Group type: COMPARATOR
Intervention: 18 Gy cranial irradiation
Number of subjects: 136
Study 2346334 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children (<2 years)
Number of subjects: 136
Study 2346334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial computed tomography abnormalities
Number of subjects: 136
Study 760750 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-adrenoceptor blockade)
Number of subjects: 0
Study 760750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30777614 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Heart Tracker (HHT)
Number of subjects: 84
Study 30777614 — intervention group
Group type: COMPARATOR
Intervention: Usual patient discharge handouts (Control)
Number of subjects: 84
Study 27976801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Fla-X positivity at baseline
Number of subjects: 169
Study 27976801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Fla-X positivity at 12 months
Number of subjects: 169
Study 27976801 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of all four antibacterial antibodies (anti-CBir1, anti-OmpC, anti-A4-Fla2, anti-Fla-X) at baseline
Number of subjects: 169
Study 27976801 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline quartile sum score for all six antimicrobial antibodies
Number of subjects: 169
Study 25721604 — intervention group
Group type: EXPERIMENTAL
Intervention: 4xEC-4xDoc
Number of subjects: 772
Study 25721604 — intervention group
Group type: COMPARATOR
Intervention: 6xCEF/CMF
Number of subjects: 772
Study 25306557 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg benralizumab
Number of subjects: 609
Study 25306557 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg benralizumab
Number of subjects: 609
Study 25306557 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab (any dose)
Number of subjects: 609
Study 25306557 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 609
Study 25306557 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab
Number of subjects: 609
Study 22039087 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction oxaliplatin, folinic acid and 5‐FU followed by CRT and surgery
Number of subjects: 57
Study 22039087 — intervention group
Group type: COMPARATOR
Intervention: Preoperative CRT with 5‐fluorouracil (5‐FU) continuous infusion followed by surgery
Number of subjects: 57
Study 19220764 — intervention group
Group type: EXPERIMENTAL
Intervention: New gustatory stimulant of salivary secretion containing weaker malic acid, fluoride, and xylitol
Number of subjects: 120
Study 19220764 — intervention group
Group type: COMPARATOR
Intervention: Traditional citric acid-based gustatory stimulant
Number of subjects: 120
Study 17241860 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalamine 2.4 g/day
Number of subjects: 343
Study 17241860 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalamine 4.8 g/day
Number of subjects: 343
Study 17241860 — intervention group
Group type: EXPERIMENTAL
Intervention: ASACOL 2.4 g/day
Number of subjects: 343
Study 17241860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 15066738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree oil regimen (10% cream, 5% body wash for 5 days)
Number of subjects: 224
Study 15066738 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (mupirocin 2% nasal ointment, chlorhexidine gluconate 4% soap, silver sulfadiazine 1% cream for 5 days)
Number of subjects: 224
Study 15066738 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin 2% nasal ointment
Number of subjects: 224
Study 15066738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree cream
Number of subjects: 224
Study 15066738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree treatment
Number of subjects: 224
Study 12086554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (Kaletra)
Number of subjects: 0
Study 9585043 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintimammography (740 MBq of Tc-99m sestamibi)
Number of subjects: 70
Study 9585043 — intervention group
Group type: COMPARATOR
Intervention: X-ray mammography
Number of subjects: 70
Study 1888324 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (special kind of behaviour therapy)
Number of subjects: 192
Study 1888324 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 192
Study 6337951 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (450 mg/day)
Number of subjects: 18
Study 6337951 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (combined with hydrochlorothiazide)
Number of subjects: 18
Study 6337951 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (up to 100 mg/day)
Number of subjects: 18
Study 6337951 — intervention group
Group type: COMPARATOR
Intervention: Captopril monotherapy
Number of subjects: 18
Study 31201110 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation using intensity-modulated radiotherapy (IMRT)
Number of subjects: 41
Study 31201110 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance programme
Number of subjects: 41
Study 31201110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosimetry audits for IMRT
Number of subjects: 41
Study 31201110 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-trial feedback
Number of subjects: 41
Study 30367116 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity intervals (VII) at 90% of heart rate reserve (HRR)
Number of subjects: 10
Study 30367116 — intervention group
Group type: COMPARATOR
Intervention: Control session of 45 minutes of walking at 45-55% of HRR
Number of subjects: 10
Study 26453773 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF plus peginterferon for 48 weeks (group A)
Number of subjects: 740
Study 26453773 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF plus peginterferon for 16 weeks followed by TDF for 32 weeks (group B)
Number of subjects: 740
Study 26453773 — intervention group
Group type: COMPARATOR
Intervention: TDF for 120 weeks (group C)
Number of subjects: 740
Study 26453773 — intervention group
Group type: COMPARATOR
Intervention: peginterferon for 48 weeks (group D)
Number of subjects: 740
Study 24215302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 60
Study 22129616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 0 ml (V0)
Number of subjects: 9
Study 22129616 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 100 ml (V100)
Number of subjects: 9
Study 22129616 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 300 ml (V300)
Number of subjects: 9
Study 22129616 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 500 ml (V500)
Number of subjects: 9
Study 22129616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension (all volumes)
Number of subjects: 9
Study 20697246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Number of subjects: 20
Study 20697246 — intervention group
Group type: COMPARATOR
Intervention: Control (previous heel sticks without mechanical vibration)
Number of subjects: 20
Study 18494756 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache Management Program (HMP)
Number of subjects: 124
Study 18494756 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptans
Number of subjects: 124
Study 16805931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fentanyl with saline
Number of subjects: 120
Study 16805931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fentanyl with ketoprofen (1.5 mg kg‐1)
Number of subjects: 120
Study 16805931 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative remifentanil with saline
Number of subjects: 120
Study 16805931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil with ketoprofen
Number of subjects: 120
Study 12505963 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene group (n = 20) received clonidine 150 micro g in 15 mL of saline through the catheter
Number of subjects: 40
Study 12505963 — intervention group
Group type: COMPARATOR
Intervention: Systemic group (n = 20) received 15 mL of saline through the catheter and clonidine 150 micro g (1 mL) subcutaneously
Number of subjects: 40
Study 12505963 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene group
Number of subjects: 40
Study 12505963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 10606932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 16
Study 10606932 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 9075128 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 5 mg once daily for 4 weeks
Number of subjects: 18
Study 8371932 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon alpha‐2a (3 million units/m2) every other day for 8 weeks
Number of subjects: 20
Study 8371932 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (Control)
Number of subjects: 20
Study 3522749 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin (amoxycillin-clavulanic acid)
Number of subjects: 67
Study 3522749 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 67
Study 29447947 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-W GreenLight photoselective vaporization (GL PV)
Number of subjects: 238
Study 29447947 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 238
Study 27576073 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program, provider education, and one-on-one coaching of practice-based immunization champions
Number of subjects: 70549
Study 27576073 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention groups
Number of subjects: 70549
Study 27576073 — intervention group
Group type: COMPARATOR
Intervention: Maintenance groups
Number of subjects: 70549
Study 27576073 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 70549
Study 24906043 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-Disable syringe with a 23 gauge and 25 mm needle
Number of subjects: 1000
Study 24906043 — intervention group
Group type: COMPARATOR
Intervention: Disposable syringe with a 24 gauge and 25 mm needle
Number of subjects: 1000
Study 24906043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Auto-Disable and Disposable syringes)
Number of subjects: 1000
Study 21494820 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 1458
Study 21494820 — intervention group
Group type: COMPARATOR
Intervention: Non-statin users
Number of subjects: 1458
Study 20219638 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 0
Study 20219638 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 20219638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18984557 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention with high-personalized message source
Number of subjects: 1866
Study 18984557 — intervention group
Group type: COMPARATOR
Intervention: Web-based smoking cessation intervention with low-personalized message source
Number of subjects: 1866
Study 18984557 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention with high-tailored outcome expectation
Number of subjects: 1866
Study 18984557 — intervention group
Group type: COMPARATOR
Intervention: Web-based smoking cessation intervention with low-tailored outcome expectation
Number of subjects: 1866
Study 18984557 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention with high-depth tailored self-efficacy components
Number of subjects: 1866
Study 18984557 — intervention group
Group type: COMPARATOR
Intervention: Web-based smoking cessation intervention with low-depth tailored self-efficacy components
Number of subjects: 1866
Study 18984557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential exposure to program sections over 5 weeks
Number of subjects: 1866
Study 18984557 — intervention group
Group type: COMPARATOR
Intervention: Unified Web program with all sections available at once
Number of subjects: 1866
Study 15991505 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia alone (Group A1, n=30)
Number of subjects: 102
Study 15991505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% nitrous oxide (Group N1, n=27)
Number of subjects: 102
Study 15991505 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia alone (Group A3, n=23)
Number of subjects: 102
Study 15991505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% nitrous oxide (Group N3, n=22)
Number of subjects: 102
Study 12410648 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (300 micro g) nasal spray
Number of subjects: 39
Study 12410648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10514155 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioural counselling by practice nurses
Number of subjects: 883
Study 10514155 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 883
Study 8792950 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 8792950 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg and Hydrochlorothiazide 12.5 mg
Number of subjects: 0
Study 8792950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8792950 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 1881718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 287
Study 1881718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 6336877 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 733
Study 6336877 — intervention group
Group type: COMPARATOR
Intervention: Light exercise (Control)
Number of subjects: 733
Study 31764363 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative intravenous dexamethasone
Number of subjects: 64
Study 31764363 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 64
Study 28985960 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75mg (3 × 25 mg) Phase II capsules
Number of subjects: 61
Study 28985960 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75mg (3 × 25 mg) Phase III capsules
Number of subjects: 61
Study 26795265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dietary supplement (2 capsules/day)
Number of subjects: 40
Study 26795265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 40
Study 26795265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dietary supplement (10 or 50 mg/kg orally)
Number of subjects: 40
Study 26795265 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (2% DMSO)
Number of subjects: 40
Study 24070494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 μg
Number of subjects: 8
Study 24070494 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 μg
Number of subjects: 8
Study 24070494 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol xinafoate (SLM) 50 μg
Number of subjects: 8
Study 24070494 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination FP 100 μg + SLM 50 μg
Number of subjects: 8
Study 24070494 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SLM) 10(‐8) mol/L with Fluticasone (FP) 10(‐9) mol/L
Number of subjects: 8
Study 24070494 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SLM) 10(‐9) mol/L with Fluticasone (FP) 10(‐11) mol/L
Number of subjects: 8
Study 21795438 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting metabolic rate (RMR) measured in obese pregnant women
Number of subjects: 23
Study 21795438 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic cost of walking measured in obese pregnant women
Number of subjects: 23
Study 21795438 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected walking (SSW) speed measured in obese pregnant women
Number of subjects: 23